ABRE Study

  • Research type

    Research Study

  • Full title

    A multi-center, non-randomized study to evaluate the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction.

  • IRAS ID

    220423

  • Contact name

    Sarah Willey

  • Contact email

    sarah.a.willey@medtronic.com

  • Sponsor organisation

    Medtronic Inc

  • Clinicaltrials.gov Identifier

    NCT03038438

  • Clinicaltrials.gov Identifier

    G160163/A001, IDE number

  • Duration of Study in the UK

    5 years, 0 months, 0 days

  • Research summary

    The Abre Study is a multi-center, non-randomized study to evaluate the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction. The purpose of the study is to evaluate the safety and effectiveness of the Abre venous self-expanding stent system for treatment of symptomatic iliofemoral venous outflow obstruction in patients with venous occlusive disease. Currently several stents are CE-marked for this indication. The Abre system is CE marked in Europe and will be used within its intended use. A review of available literature on the use of stents for the treatment of venous obstructive disease shows that angioplasty and venous stenting are safe and effective in patients presenting with acute deep vein thrombosis, chronic postthrombotic syndrome (PTS) and chronic nonthrombotic iliac vein lesion (NIVL). The Abre system has been developed specifically for this need.
    The collected data will be used to support regulatory applications to seek market approval in the US and potentially other geographies.
    A maximum of 200 consented subjects will be included in the study with a hypothesis-based 30-day composite safety endpoint and a hypothesis-based 12-month effectiveness endpoint to be tested against performance goals which are based on data derived from a comprehensive literature review. Subjects who are implanted with the Abre stent will be followed for 3 years. They will have scheduled follow-up visits at 30-days, 6-, 12-, 24-, and 36-months post index procedure.

  • REC name

    London - Dulwich Research Ethics Committee

  • REC reference

    17/LO/0797

  • Date of REC Opinion

    31 Jul 2017

  • REC opinion

    Further Information Favourable Opinion